Evidence map›Paper›PMID 35889301›Full record

ReviewMolecules (Basel, Switzerland)2022

Cyclic Peptides for the Treatment of Cancers: A Review.

Dalifa Ramadhani, Rani Maharani, Amirah Mohd Gazzali, Muchtaridi Muchtaridi

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. CyclicMPNN: Stable Cyclic Peptide Sequence Generation.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Therapeutic Potential of Stylissatin A and Related Cyclic Peptides From Marine Sponges.Journal of peptide science : an official publication of the European Peptide Society · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Cyclic Lipopeptides as Selective Anticancer Agents:Anti-cancer agents in medicinal chemistry · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Dalifa RamadhaniDepartment of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang KM 21, Sumedang 45363, Indonesia.ORCID 0000-0003-3880-7718
Rani MaharaniDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jatinangor 45363, Indonesia.
Amirah Mohd GazzaliSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, USM, Penang 11800, Malaysia.ORCID 0000-0003-4469-1969
Muchtaridi MuchtaridiDepartment of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang KM 21, Sumedang 45363, Indonesia.ORCID 0000-0002-6156-8025
Padjadjaran University · IDUniversiti Sains Malaysia · MY

Funding

Universitas Padjadjaran 2203/UN6.3.1/PT.00/2022
6 · The paper itself

Abstract

Cyclic peptides have been widely reported to have therapeutic abilities in the treatment of cancer. This has been proven through in vitro and in vivo studies against breast, lung, liver, colon, and prostate cancers, among others. The multitude of data available in the literature supports the potential of cyclic peptides as anticancer agents. This review summarizes the findings from previously reported studies and discusses the different cyclic peptide compounds, the sources, and their modes of action as anticancer agents. The prospects and future of cyclic peptides will also be described to give an overview on the direction of cyclic peptide development for clinical applications.

Indexed as

Antineoplastic AgentsNeoplasmsHumansPeptidesPeptides, CyclicAntineoplastic AgentsPeptidesPeptides, Cyclicanticancercyclic peptidein vitroin vivomechanism of anticancer

Identifiers

PMID35889301
PMCPMC9317348
OpenAlexW4285095102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.